Calquence (Acalabrutinib Maleate) Patent Expiration, LOE Window & CMS Spending

Calquence (Acalabrutinib Maleate) by AstraZeneca: FDA Orange Book core substance LOE 2036-07-01, 0 AB generics, $1.77B 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstraZeneca
FDA Application & PathwayN210259 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-07-01
Last Listed Patent or Exclusivity Date2036-07-01
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.77B
2024 Medicare Part D Spend$1.70B
2024 Medicaid Spend$69.6M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.